Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Change in Cash (2016 - 2025)

Historic Change in Cash for Niagen Bioscience (NAGE) over the last 15 years, with Q3 2025 value amounting to $3.8 million.

  • Niagen Bioscience's Change in Cash fell 1544.43% to $3.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $31.9 million, marking a year-over-year increase of 46696.89%. This contributed to the annual value of $17.3 million for FY2024, which is 15181.58% up from last year.
  • Per Niagen Bioscience's latest filing, its Change in Cash stood at $3.8 million for Q3 2025, which was down 1544.43% from $4.9 million recorded in Q2 2025.
  • In the past 5 years, Niagen Bioscience's Change in Cash registered a high of $28.0 million during Q1 2021, and its lowest value of -$7.2 million during Q1 2022.
  • Its 5-year average for Change in Cash is $2.5 million, with a median of $552000.0 in 2023.
  • As far as peak fluctuations go, Niagen Bioscience's Change in Cash crashed by 50057.42% in 2021, and later soared by 446500.0% in 2025.
  • Quarter analysis of 5 years shows Niagen Bioscience's Change in Cash stood at -$4.9 million in 2021, then soared by 247.02% to $7.2 million in 2022, then plummeted by 92.31% to $552000.0 in 2023, then soared by 2121.38% to $12.3 million in 2024, then plummeted by 68.88% to $3.8 million in 2025.
  • Its last three reported values are $3.8 million in Q3 2025, $4.9 million for Q2 2025, and $11.0 million during Q1 2025.